IBRX vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ImmunityBio exhibits a severe divergence between fundamental financial health and growth trajectory. The deterministic baseline is critical, with a Piotroski F-Score of 1/9 indicating extreme financial weakness and a negative Price/Book ratio (-14.71) signaling that liabilities exceed assets. However, this is countered by explosive YoY revenue growth of 407% and a strong current ratio of 5.10, providing a necessary liquidity runway. While analysts maintain a 'strong_buy' rating based on future potential, the current valuation is speculative and disconnected from traditional value metrics.
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
IBRX vs JNJ: Head-to-Head Comparison
This page compares ImmunityBio, Inc. (IBRX) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.